Advanced Microbubbles is a biotech company dedicated to improving drug delivery in medical research. They specialize in the development and sale of size-isolated monodisperse microbubble ultrasound contrast agents (UCAs). These agents are designed to address a major problem in anticancer drug delivery, where less than 1% of injected drugs can effectively penetrate diseased areas due to biological barriers such as the blood-brain barrier or tumor-endothelium.

What sets Advanced Microbubbles apart is their innovative solution involving ultrasound-triggered microbubbles. These microbubbles have been optimized for diagnostic imaging and have been proven safe. They enable the safe and noninvasive opening of the blood-brain barrier for drug delivery, improve the efficacy and survival benefits of immunotherapy for pancreatic cancer treatment, and allow for the treatment of high-risk neuroblastoma with liposomal doxorubicin (L-Dox) while eliminating its toxic side effects.

Advanced Microbubbles' technology is compatible with a wide range of therapies including gene therapies, immunotherapies, and chemotherapies. Their aim is to provide a cost-effective and efficient method of drug delivery without the need for expensive drug modification